Cangene announces approval of liquid formulation of WinRho(R) SDF in Canada



    Listed TSX, Symbol: CNJ

    TORONTO and WINNIPEG, Nov. 28 /CNW/ - Cangene Corporation today announces
that Health Canada has approved the liquid formulation of Cangene's WinRho(R)
SDF (Rho(D) Immune Globulin (Human)). WinRho(R) SDF is used to treat hemolytic
disease of the newborn and a bleeding disorder called immune thrombocytopenic
purpura (ITP). It can also be used to treat certain transfusion reactions.
WinRho(R) SDF Liquid provides a convenient alternative to the lyophilized
(freeze-dried) version of the therapeutic by eliminating the need for
reconstitution of the product prior to administration.
    "Ease of administration can be an important feature for a drug, and
liquid formulations offer increased convenience to physicians," said Dr. John
Langstaff, Cangene's president and CEO. "This convenient formulation of
WinRho(R) SDF has been available since 2006 in the U.S. and we are pleased to
be able to provide it to physicians in Canada".
    WinRho(R) SDF is a hyperimmune antibody preparation specific for a
certain type of red blood cell and it is derived from human plasma. It is sold
in more than 40 countries worldwide and is distributed in Canada through
Canadian Blood Services and Héma-Québec. Cangene manufactures both the
lyophilized and the liquid versions of the product in its facility in
Winnipeg. Labelling and other requirements for launching the new version of
the product in Canada should be completed in the next several months.
Additional information about WinRho(R) SDF, including important safety and
prescribing information, is available on Cangene's website at www.cangene.com.

    About Cangene Corporation

    Cangene is one of Canada's largest and earliest biopharmaceutical
companies. It was founded in 1984 and is headquartered in Winnipeg, Manitoba.
Cangene has aproximately 650 employees in eight locations across North
America. It operates three large manufacturing facilities - two in Winnipeg,
Manitoba and one in Baltimore, Maryland - where it produces its own products
and undertakes contract manufacturing for a number of companies. Cangene
operates three U.S. and one Canadian plasma-collection facilities. In
addition, it has a regulatory affairs, sales and investor relations office in
Mississauga, Ontario.
    The Company uses patented manufacturing processes to produce
plasma-derived and recombinant therapeutic proteins. Cangene has three FDA and
Health Canada-approved products and a fourth that has been approved in Canada
only. One of its recombinant protein products has received an approvable
letter from the FDA and another has been submitted for regulatory review in
Canada. In addition, the Company has several more products in development at
various stages. Three of Cangene's products have been accepted into the U.S.
Strategic National Stockpile-botulism antitoxin, anthrax immune globulin and
vaccinia immune globulin, a product used to counteract certain complications
arising from smallpox vaccination.
    Capitalizing on its drug manufacturing expertise, Cangene also operates a
significant contract research and manufacturing business using its Winnipeg
facilities and the resources of Baltimore, Maryland-based Chesapeake
Biological Laboratories, Inc. (a wholly owned subsidiary). An expansion in
2006 at the Winnipeg location increased the Company's capacity to fractionate
plasma to accommodate the growing manufacturing requirements. Cangene's
website, www.cangene.com, includes product and investor information, including
past news releases. Chesapeake's website is www.cblinc.com.

    Forward-looking information

    The reader should be aware that Cangene's businesses are subject to risks
and uncertainties that cannot be predicted or quantified; consequently, actual
results may differ materially from past results and those expressed or implied
by any forward-looking statements. Factors that could cause or contribute to
such risks or uncertainties include, but are not limited to: the regulatory
environment including the difficulty of predicting regulatory outcomes;
changes in the value of the Canadian dollar; the Company's reliance on a small
number of customers including government organizations; the demand for new
products and the impact of competitive products, service and pricing;
availability and cost of raw materials, especially the cost, availability and
antibody concentration in plasma; fluctuations in operating results;
government policies or actions; progress and cost of clinical trials; reliance
on key strategic relationships; costs and possible development delays
resulting from use of legal, regulatory or legislative strategies by the
Company's competitors; uncertainty related to intellectual property protection
and potential cost associated with its defence; the Company's exposure to
lawsuits, and other matters beyond control of management.
    Risks and uncertainties are discussed more extensively in the MD&A
section of the Company's most recent annual report and annual information
form, which are available on the Company's website or on SEDAR at
www.sedar.com. Scientific information that relates to unapproved products or
unapproved uses of products is preliminary and investigative. No conclusions
can or should be drawn regarding the safety or efficacy of such products. Only
regulatory authorities can determine whether products are safe and effective
for the uses being investigated. Healthcare professionals are directed to
refer to approved labelling for products and not rely on information presented
in news releases. Drug names and prescribing information may differ in various
countries.
    The cautionary statements referred to above should be considered in
connection with all written or oral statements, especially forward-looking
statements, that are made by the Company or by persons acting on its behalf
and in conjunction with its periodic filings with Securities Commissions,
including those contained in the Company's news releases and most recently
filed annual information form. Forward-looking statements can be identified by
the use of words such as "expects", "plans", "will", "believes", "estimates",
"intends", "may", "bodes" and other words of similar meaning (including
negative and grammatical variations). Should known or unknown risks or
uncertainties materialize, or should management's assumptions prove
inaccurate, actual results could vary materially from those anticipated. The
Company undertakes no obligation to publicly make or update any
forward-looking statements, except as required by applicable law.

    %SEDAR: 00002351E




For further information:

For further information: John McMillan at (204) 275-4310 or by email at
jmcmillan@cangene.com

Organization Profile

Cangene Corporation

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890